Exemestane vs HMG
FDA Approved vs Extensively Studied
synergistic Mechanism-based · 70% HMG helps manage estrogen conversion from Exemestane. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
Exemestane HMG
Weight 296.40 Da —
Half-life ~24 hours ~32 hours (FSH component: 39-54 hours)
Type Steroidal aromatase inhibitor (irreversible, suicide inhibitor) Gonadotropin mixture
Key Benefits
Exemestane
01 Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
02 Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
03 Potent estrogen suppression (85-95% reduction in estradiol at full dose)
04 Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
05 Prevents gynecomastia during testosterone or aromatizable steroid cycles
06 Reduces estrogen-driven water retention, bloating, and blood pressure elevation
07 Oral dosing with once-daily or less frequent administration for cycle support
HMG
01 FDA-approved for fertility treatment
02 Stimulates ovarian follicle development
03 Contains both FSH and LH naturally
04 Promotes spermatogenesis in men
05 Cost-effective alternative to recombinant FSH
06 LH activity may improve fertilization rates
07 Long clinical track record
08 Lower OHSS incidence with HP-hMG
Dosing Protocols
Exemestane
12.5mg EOD or 25mg E3D (estrogen management) / Every other day to every 3 days (cycle support); daily (breast cancer)
HMG
75-150 IU for ovulation induction; 150-300 IU for IVF / Daily during stimulation phase (7-12 days)
Ovulation induction 75-150 IU Daily
IVF stimulation 150-300 IU Daily for 7-12 days
Male fertility 75-150 IU 2-3x weekly
Side Effects
Exemestane
Joint pain and stiffness (generally less severe than with anastrozole due to mild androgenic activity)
Fatigue and general malaise
Hot flashes or flushing
Mood changes (irritability, flat affect, low mood)
Headache
Increased sweating
HMG
Injection site reactions
Abdominal discomfort
Ovarian enlargement
Mood changes
Headache
Contraindications
Known hypersensitivity to exemestane or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with other aromatase inhibitors (anastrozole, letrozole)
Primary ovarian failure
Uncontrolled thyroid or adrenal dysfunction
Sex hormone-dependent tumors
Abnormal uterine bleeding of unknown cause
Ovarian cysts (not due to PCOS)
Pregnancy
Research Evidence
Exemestane HMG
Status FDA Approved Extensively Studied
References 5 studies 4 studies
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.